A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study)

2014 ◽  
Vol 167 (2) ◽  
pp. 243-251 ◽  
Author(s):  
Huyen Tran ◽  
Tim Brighton ◽  
Andrew Grigg ◽  
Simon McRae ◽  
Joanna Dixon ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Fixed Dose ◽  
Chronic Idiopathic Thrombocytopenic Purpura ◽  
Open Label ◽  
Thrombocytopenic Purpura ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy

scholarly journals Safety and Efficacy of Oral Human Parathyroid Hormone (1‐34) in Hypoparathyroidism: An Open‐Label Study

2021 ◽  
Author(s):  
Sofia Ish‐Shalom ◽  
Yoseph Caraco ◽  
Nariman Saba Khazen ◽  
Michal Gershinsky ◽  
Auryan Szalat ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Human Parathyroid Hormone ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy

scholarly journals A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis

2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Daniel J. Lovell ◽  
Jason A. Dare ◽  
Megan Francis-Sedlak ◽  
Julie Ball ◽  
Brian D. LaMoreaux ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Fixed Dose ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Adolescent Patients

scholarly journals A179 CANADIAN INVOLVEMENT IN THE EVALUATION OF NOVEL THERAPY FOR DIABETIC GASTROPARESIS: OVERVIEW OF PLEDGE TRIALS

2020 ◽  
Vol 3 (Supplement_1) ◽  
pp. 45-47
Author(s):  
L W Liu ◽  
M Syrzycka ◽  
P Janiszewski ◽  
L Kemps ◽  
B Degeronimo
Keyword(s):  
Diabetic Gastroparesis ◽  
Extension Study ◽  
Open Label ◽  
Double Blind ◽  
Open Label Study ◽  
Label Study ◽  
Safety And Efficacy ◽  
Double Blind Placebo ◽  
The Third ◽  
Parallel Group

Abstract Background Diabetic gastroparesis(DG) is a serious, chronic complication of type 1 or 2 diabetes mellitus(DM) presenting with a delay in gastric emptying(GE). An estimated 3 million Canadians have been diagnosed with DM; up to 5% of these patients may develop DG. DG can result in poor glycemic control, recurrent nausea and vomiting, often resulting in hospitalization. To date, no effective treatments are available. A phase 2 study showed that relamorelin (RLM), a synthetic ghrelin agonist, was safe and effective in treating DG. Investigators across Canada are participating in a set of phase 3 international trials of RLM in the treatment of DG. Aims To report the Canadian involvement in the international effort to evaluate the safety and efficacy of RLM in the treatment of DG. PLEDGE is a set of 5 trials: two identical 12-week studies, a 46-week extension study, a 52-week exposure study, and an open-label extension study. Collectively, the data from these studies will help to evaluate the safety and efficacy of RLM, a novel treatment for Canadian patients living with DG. Methods Four global, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies compare the efficacy of RLM with placebo in participants with DG using composite endpoints of nausea, abdominal pain, postprandial fullness, bloating. Participants are randomized to RLM 10μg or placebo subcutaneously (SC) twice daily groups. The open-label continuation of treatment will follow participants until RLM becomes commercially available to provide long-term safety information to support the safe use of RLM as a chronic treatment of DG. As seen in Figure 1, participants from the two 12-week studies will rollover into the third study that will continue for 46 weeks. The fourth study will enroll participants that were not randomized in the first two studies because their symptoms were less severe and will also accept new participants. Participants will be randomized 2:1 to RLM 10μg or placebo SC twice daily groups. Participants from the third and fourth studies have the option to enroll in the open-label study. Results Target enrollment is approx. 1800 participants for the 4 global, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies and 1000 participants for the open label study. 700 sites are expected to participate globally; 15 Canadian sites in 6 provinces are participating. Conclusions Canadian centers are actively involved in the PLEDGE trials to help determine the efficacy and safety of RLM, a potential new treatment for DG. This publication increases awareness of the Canadian gastroenterology community, providing an option to refer interested patients to PLEDGE study centers. PLEDGE Studies (NCT03285308, NCT03426345, NCT03420781, NCT03383146, NCT03786380): Placebo-controlled, randomized RLM-MD-01/02/03/04 and open-label study 3071-305-020 to study the safety and efficacy of relamorelin for the treatment of diabetic gastroparesis Funding Agencies None

Sign in / Sign up

Export Citation Format

Share Document